Companies › Shanghai RAAS Blood Products
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Hematology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SR604 Von Willebrand factor (VWF) mimetic or functional VWF replacement | – | Phase 2 | Von Willebrand Disease (VWD); Hemophilia A | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07644832 | SR604 | Phase 1 | Hemophilia A | Hematology | Dec 2026 |
| NCT07640893 | SR604 | Phase 2 | Von Willebrand Disease (VWD) | Hematology | Dec 2027 |
No annotated target.
–
S-INFINITY Pharmaceuticals Prothya Biosolutions Imara Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.